• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Theriva Biologics Inc.

    11/12/25 4:11:24 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TOVX alert in real time by email
    DEFA14A 1 tm2530900d1_defa14a.htm DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    (Rule 14a-101)

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material Pursuant to §240.14a-12

     

    Theriva Biologics, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     

     

     

     

    Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V81391-S25170 THERIVA BIOLOGICS, INC The Board of Directors recommends you vote FOR proposals 1 and 2: Note: To transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting. 1. To approve, pursuant to Section 713(a) of the NYSE American Company Guide and the terms of an inducement agreement, the issuance of up to an aggregate of 16,184,560 shares of our common stock upon the exercise of our common stock purchase warrants issued to institutional investors in our private placement offering, which closed on October 17, 2025 (the "Warrant Exercise Proposal"). 2. To approve a proposal to adjourn the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Warrant Exercise Proposal. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. ! ! ! For Against Abstain ! ! ! SCAN TO VIEW MATERIALS & VOTEw THERIVA BIOLOGICS, INC 9605 MEDICAL CENTER DRIVE, SUITE 270 ROCKVILLE, MARYLAND 20850 VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time the day before the meeting date. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

    V81392-S25170 Important Notice Regarding the Availability of Proxy Materials for the Special Meeting: The Notice of Meeting, proxy statement and proxy card are available at www.proxyvote.com. THERIVA BIOLOGICS, INC SPECIAL MEETING OF STOCKHOLDERS DECEMBER 15, 2025 AT 9:00 A.M. (EASTERN TIME) THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned stockholder hereby appoints Steven A. Shallcross as proxy, with the power to appoint his substitute, and hereby authorizes him to represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of THERIVA BIOLOGICS, INC. that the undersigned is entitled to vote at the Special Meeting of Stockholders to be held 9:00 a.m. (eastern time), on December 15, 2025 at the Company’s principal office at 9605 Medical Center Dr, Suite 270 Rockville MD 20850, or any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors’ recommendations. Continued and to be signed on reverse side

    Get the next $TOVX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TOVX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TOVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results

    - Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO) Annual Congress 2025 - - Next generation oncolytic virus VCN-12 preclinical data presented at the 32nd Annual Congress European Society of Gene & Cell Therapy (ESGCT) - - Cash and cash equivalents of $7.5 millon as of September 30, 2025; recent capital raises increase cash to $15.5 million as of November 10, 2025 and extends cash runway into Q1 2027 - ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeut

    11/12/25 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theriva Biologics Provides Response to Unusual Market Action

    ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today that the Company had become aware of unusual trading activity in its common stock on the NYSE American (the "NYSE") on October 24, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company Guide. The Company has made inquiries and does not believe corrective actions are appropriate. The Company is further announcing that there has been no material development in its business and affairs not pre

    10/24/25 2:31:47 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

    ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced its entry into a warrant inducement agreement with existing institutional investors of the Company for the immediate exercise of warrants to purchase up to 7,360,460 of common stock (the "Existing Warrants") at a reduced exercise price of $0.54 per share for gross cash proceeds of approximately $4.0 million before deducting fees and other transaction expenses. The offer to exercise will remain open until 11:30 AM ET for up to an a

    10/16/25 8:11:13 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Wolf Jeffrey Alan

    4 - Theriva Biologics, Inc. (0000894158) (Issuer)

    5/1/25 4:02:16 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and CFO Shallcross Steven A

    4 - Theriva Biologics, Inc. (0000894158) (Issuer)

    5/1/25 4:01:54 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kraws Jeffrey J

    4 - Theriva Biologics, Inc. (0000894158) (Issuer)

    5/1/25 4:01:06 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TOVX
    Financials

    Live finance-specific insights

    View All

    Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

    – The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised - - VIRAGE remains on track to complete enrollment in the first half of 2024- - As of December 31, 2023, Theriva Biologics reports $23.2 million in cash, which is expected to provide runway into the first quarter of 2025 - - Conference call and webcast to be held on Monday, March 25 at 8:30 a.m. ET - ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing ther

    3/25/24 7:30:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

    ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, March 25, 2024, at 8:30 a.m. ET to discuss its financial results for the full year ended December 31, 2023 and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13744453. Participants are asked to dial-in 15 minutes before the start of the call to register. Investors and th

    3/19/24 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

    - VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with prior clinical trials - - Presented survival outcomes data from the Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck at the European Society for Medical Oncology (ESMO) Congress 2023 - - Data from the Phase 1 investigator-sponsored stu

    11/13/23 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Theriva Biologics Inc.

    SC 13G - Theriva Biologics, Inc. (0000894158) (Subject)

    10/3/24 4:12:12 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Theriva Biologics Inc.

    SC 13G - Theriva Biologics, Inc. (0000894158) (Subject)

    10/2/24 10:53:47 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TOVX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Theriva Biologics Inc.

    DEFA14A - Theriva Biologics, Inc. (0000894158) (Filer)

    11/12/25 4:11:24 PM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Theriva Biologics Inc.

    10-Q - Theriva Biologics, Inc. (0000894158) (Filer)

    11/12/25 8:16:27 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theriva Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Theriva Biologics, Inc. (0000894158) (Filer)

    11/12/25 8:10:35 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TOVX
    Leadership Updates

    Live Leadership Updates

    View All

    Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

    -Appointment expected to aid advancement of Theriva's discovery program and strengthen collaboration with the Institut Catala d'Oncologia (ICO) and the Biomedical Research Institute of Bellvitge (IDIBELL)- ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE:TOVX), ("Theriva" or the "Company"), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the appointment of Dr. Ramon Alemany as Senior Vice President of Discovery, effective immediately. Dr. Alemany will oversee Theriva's discovery and development pipeline and will continue to serve as Chair of the Scientific Advisory Board. D

    5/23/23 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care